Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 163 entries
Sorted by: Best Match Show Resources per page
A case report of fatal harlequin ichthyosis: Insights into infectious and respiratory complications.

JAAD case reports

Parikh K, Brar K, Glick JB, Flamm A, Glick SA.
PMID: 27536717
JAAD Case Rep. 2016 Aug 03;2(4):301-3. doi: 10.1016/j.jdcr.2016.06.011. eCollection 2016 Jul.

No abstract available.

Cite
Parikh K, Brar K, Glick JB, et al. A case report of fatal harlequin ichthyosis: Insights into infectious and respiratory complications. JAAD Case Rep. 2016;2(4):301-3doi: 10.1016/j.jdcr.2016.06.011.
Parikh, K., Brar, K., Glick, J. B., Flamm, A., & Glick, S. A. (2016). A case report of fatal harlequin ichthyosis: Insights into infectious and respiratory complications. JAAD case reports, 2(4), 301-3. https://doi.org/10.1016/j.jdcr.2016.06.011
Parikh, Kruti, et al. "A case report of fatal harlequin ichthyosis: Insights into infectious and respiratory complications." JAAD case reports vol. 2,4 (2016): 301-3. doi: https://doi.org/10.1016/j.jdcr.2016.06.011
Parikh K, Brar K, Glick JB, Flamm A, Glick SA. A case report of fatal harlequin ichthyosis: Insights into infectious and respiratory complications. JAAD Case Rep. 2016 Aug 03;2(4):301-3. doi: 10.1016/j.jdcr.2016.06.011. eCollection 2016 Jul. PMID: 27536717; PMCID: PMC4976614.
Copy Download .nbib Format: NLM
Dermatopathology quiz: Keratotic papules of the palms.

Indian dermatology online journal

Flamm A, Xie Q, Polley DC, Vanstory L, Elston DM.
PMID: 27990395
Indian Dermatol Online J. 2016 Nov-Dec;7(6):536-537. doi: 10.4103/2229-5178.193904.

No abstract available.

Cite
Flamm A, Xie Q, Polley DC, et al. Dermatopathology quiz: Keratotic papules of the palms. Indian Dermatol Online J. 2016;7(6):536-537doi: 10.4103/2229-5178.193904.
Flamm, A., Xie, Q., Polley, D. C., Vanstory, L., & Elston, D. M. (2016). Dermatopathology quiz: Keratotic papules of the palms. Indian dermatology online journal, 7(6), 536-537. https://doi.org/10.4103/2229-5178.193904
Flamm, Alex, et al. "Dermatopathology quiz: Keratotic papules of the palms." Indian dermatology online journal vol. 7,6 (2016): 536-537. doi: https://doi.org/10.4103/2229-5178.193904
Flamm A, Xie Q, Polley DC, Vanstory L, Elston DM. Dermatopathology quiz: Keratotic papules of the palms. Indian Dermatol Online J. 2016 Nov-Dec;7(6):536-537. doi: 10.4103/2229-5178.193904. PMID: 27990395; PMCID: PMC5134174.
Copy Download .nbib Format: NLM
Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study.

Journal of clinical and translational hepatology

Flamm SL, Pockros PJ, Bengtsson L, Friedman M.
PMID: 26356545
J Clin Transl Hepatol. 2014 Jun;2(2):65-73. doi: 10.14218/JCTH.2014.00007. Epub 2014 Jun 15.

BACKGROUND AND AIMS: There is a paucity of information regarding similarities and differences between patients from the phase 3 studies of telaprevir and those receiving telaprevir in clinical practice.METHODS: This retrospective chart review evaluated baseline characteristics and follow-up safety...

Cite
Flamm SL, Pockros PJ, Bengtsson L, et al. Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study. J Clin Transl Hepatol. 2014;2(2):65-73doi: 10.14218/JCTH.2014.00007.
Flamm, S. L., Pockros, P. J., Bengtsson, L., & Friedman, M. (2014). Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study. Journal of clinical and translational hepatology, 2(2), 65-73. https://doi.org/10.14218/JCTH.2014.00007
Flamm, Steven L, et al. "Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study." Journal of clinical and translational hepatology vol. 2,2 (2014): 65-73. doi: https://doi.org/10.14218/JCTH.2014.00007
Flamm SL, Pockros PJ, Bengtsson L, Friedman M. Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study. J Clin Transl Hepatol. 2014 Jun;2(2):65-73. doi: 10.14218/JCTH.2014.00007. Epub 2014 Jun 15. PMID: 26356545; PMCID: PMC4521261.
Copy Download .nbib Format: NLM
Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy.

Gastroenterology & hepatology

NeSmith M, Ahn J, Flamm SL.
PMID: 27182210
Gastroenterol Hepatol (N Y). 2016 Feb;12(2):91-100.

Hepatic encephalopathy (HE) is a major complication of liver disease that leads to significant morbidity and mortality. Caring for hospitalized patients with HE is becoming more complex, and the economic burden of HE continues to rise. Defining and diagnosing...

Cite
NeSmith M, Ahn J, Flamm SL. Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy. Gastroenterol Hepatol (N Y). 2016;12(2):91-100
NeSmith, M., Ahn, J., & Flamm, S. L. (2016). Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy. Gastroenterology & hepatology, 12(2), 91-100.
NeSmith, Meghan, et al. "Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy." Gastroenterology & hepatology vol. 12,2 (2016): 91-100.
NeSmith M, Ahn J, Flamm SL. Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy. Gastroenterol Hepatol (N Y). 2016 Feb;12(2):91-100. PMID: 27182210; PMCID: PMC4865778.
Copy Download .nbib Format: NLM
[Postgraduate medical education & perspectives of the medical officers of the state (district & county physicians)].

Das Deutsche Gesundheitswesen

FLAMM E.
PMID: 13619354
Dtsch Gesundheitsw. 1958 Dec 11;13(50):1633-5.

No abstract available.

Cite
FLAMM E. Uber fachliche Fortbildung und Perspektive der ärztlichen Mitarbeiter im Staatsapparat (Bezirks- und Kreisärzte). [Postgraduate medical education & perspectives of the medical officers of the state (district & county physicians)]. Dtsch Gesundheitsw. 1958;13(50):1633-5
FLAMM, E. (1958). Uber fachliche Fortbildung und Perspektive der ärztlichen Mitarbeiter im Staatsapparat (Bezirks- und Kreisärzte). [Postgraduate medical education & perspectives of the medical officers of the state (district & county physicians)]. Das Deutsche Gesundheitswesen, 13(50), 1633-5.
FLAMM, E. "Uber fachliche Fortbildung und Perspektive der ärztlichen Mitarbeiter im Staatsapparat (Bezirks- und Kreisärzte)." [Postgraduate medical education & perspectives of the medical officers of the state (district & county physicians)]. Das Deutsche Gesundheitswesen vol. 13,50 (1958): 1633-5.
FLAMM E. Uber fachliche Fortbildung und Perspektive der ärztlichen Mitarbeiter im Staatsapparat (Bezirks- und Kreisärzte). [Postgraduate medical education & perspectives of the medical officers of the state (district & county physicians)]. Dtsch Gesundheitsw. 1958 Dec 11;13(50):1633-5. German. PMID: 13619354.
Copy Download .nbib Format: NLM
Evolutionary patterns of non-coding RNAs.

Theory in biosciences = Theorie in den Biowissenschaften

Bompfünewerer AF, Flamm C, Fried C, Fritzsch G, Hofacker IL, Lehmann J, Missal K, Mosig A, Müller B, Prohaska SJ, Stadler BM, Stadler PF, Tanzer A, Washietl S, Witwer C.
PMID: 18202870
Theory Biosci. 2005 Apr;123(4):301-69. doi: 10.1016/j.thbio.2005.01.002.

A plethora of new functions of non-coding RNAs (ncRNAs) have been discovered in past few years. In fact, RNA is emerging as the central player in cellular regulation, taking on active roles in multiple regulatory layers from transcription, RNA...

Cite
Bompfünewerer AF, Flamm C, Fried C, et al. Evolutionary patterns of non-coding RNAs. Theory Biosci. 2005;123(4):301-69doi: 10.1016/j.thbio.2005.01.002.
Bompfünewerer, A. F., Flamm, C., Fried, C., Fritzsch, G., Hofacker, I. L., Lehmann, J., Missal, K., Mosig, A., Müller, B., Prohaska, S. J., Stadler, B. M., Stadler, P. F., Tanzer, A., Washietl, S., & Witwer, C. (2005). Evolutionary patterns of non-coding RNAs. Theory in biosciences = Theorie in den Biowissenschaften, 123(4), 301-69. https://doi.org/10.1016/j.thbio.2005.01.002
Bompfünewerer, Athanasius F, et al. "Evolutionary patterns of non-coding RNAs." Theory in biosciences = Theorie in den Biowissenschaften vol. 123,4 (2005): 301-69. doi: https://doi.org/10.1016/j.thbio.2005.01.002
Bompfünewerer AF, Flamm C, Fried C, Fritzsch G, Hofacker IL, Lehmann J, Missal K, Mosig A, Müller B, Prohaska SJ, Stadler BM, Stadler PF, Tanzer A, Washietl S, Witwer C. Evolutionary patterns of non-coding RNAs. Theory Biosci. 2005 Apr;123(4):301-69. doi: 10.1016/j.thbio.2005.01.002. PMID: 18202870.
Copy Download .nbib Format: NLM
Autoimmune hepatitis.

Current treatment options in gastroenterology

Ahn J, Flamm SL.
PMID: 16313866
Curr Treat Options Gastroenterol. 2005 Dec;8(6):481-92. doi: 10.1007/s11938-005-0035-7.

Autoimmune hepatitis (AIH) is a progressive inflammatory hepatitis of unknown etiology that is responsive to immunosuppressive therapy. The diagnosis of AIH should be guided by the descriptive criteria and scoring system set forth by the International Autoimmune Hepatitis Group....

Cite
Ahn J, Flamm SL. Autoimmune hepatitis. Curr Treat Options Gastroenterol. 2005;8(6):481-92doi: 10.1007/s11938-005-0035-7.
Ahn, J., & Flamm, S. L. (2005). Autoimmune hepatitis. Current treatment options in gastroenterology, 8(6), 481-92. https://doi.org/10.1007/s11938-005-0035-7
Ahn, Joseph, and Flamm, Steven L. "Autoimmune hepatitis." Current treatment options in gastroenterology vol. 8,6 (2005): 481-92. doi: https://doi.org/10.1007/s11938-005-0035-7
Ahn J, Flamm SL. Autoimmune hepatitis. Curr Treat Options Gastroenterol. 2005 Dec;8(6):481-92. doi: 10.1007/s11938-005-0035-7. PMID: 16313866.
Copy Download .nbib Format: NLM
Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence.

Therapeutic advances in gastroenterology

Flamm SL.
PMID: 21694804
Therap Adv Gastroenterol. 2011 May;4(3):199-206. doi: 10.1177/1756283X11401774.

Hepatic encephalopathy (HE) is a common problem in patients with chronic liver disease and is characterized by diminished mentation and neuromuscular abnormalities. Symptoms range from subtle cognitive changes to coma and death. Gut-derived toxins such as ammonia are thought...

Cite
Flamm SL. Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. Therap Adv Gastroenterol. 2011;4(3):199-206doi: 10.1177/1756283X11401774.
Flamm, S. L. (2011). Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. Therapeutic advances in gastroenterology, 4(3), 199-206. https://doi.org/10.1177/1756283X11401774
Flamm, Steven L. "Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence." Therapeutic advances in gastroenterology vol. 4,3 (2011): 199-206. doi: https://doi.org/10.1177/1756283X11401774
Flamm SL. Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. Therap Adv Gastroenterol. 2011 May;4(3):199-206. doi: 10.1177/1756283X11401774. PMID: 21694804; PMCID: PMC3105611.
Copy Download .nbib Format: NLM
Liposomal delivery of alpha-Interferon to murine bladder tumor cells via transferrin receptor-mediated endocytosis.

Drug delivery

Liao WP, DeHaven J, Shao J, Chen JX, Rojanasakul Y, Lamm DL, Ma JK.
PMID: 19570002
Drug Deliv. 1998;5(2):111-8. doi: 10.3109/10717549809031386.

The role of transferrin receptor-mediated endocytosis in promoting murine bladder tumor cell (MBT2) uptake of liposomes and the antiproliferative effect of liposome-entrapped alpha-interferon (alpha-IFN) against MBT2 were investigated. Liposomes (0.11 microm) were prepared using phosphatidylcholine and phosphatidylserine in a...

Cite
Liao WP, DeHaven J, Shao J, et al. Liposomal delivery of alpha-Interferon to murine bladder tumor cells via transferrin receptor-mediated endocytosis. Drug Deliv. 1998;5(2):111-8doi: 10.3109/10717549809031386.
Liao, W. P., DeHaven, J., Shao, J., Chen, J. X., Rojanasakul, Y., Lamm, D. L., & Ma, J. K. (1998). Liposomal delivery of alpha-Interferon to murine bladder tumor cells via transferrin receptor-mediated endocytosis. Drug delivery, 5(2), 111-8. https://doi.org/10.3109/10717549809031386
Liao, W P, et al. "Liposomal delivery of alpha-Interferon to murine bladder tumor cells via transferrin receptor-mediated endocytosis." Drug delivery vol. 5,2 (1998): 111-8. doi: https://doi.org/10.3109/10717549809031386
Liao WP, DeHaven J, Shao J, Chen JX, Rojanasakul Y, Lamm DL, Ma JK. Liposomal delivery of alpha-Interferon to murine bladder tumor cells via transferrin receptor-mediated endocytosis. Drug Deliv. 1998;5(2):111-8. doi: 10.3109/10717549809031386. PMID: 19570002.
Copy Download .nbib Format: NLM
Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations.

Expert review of clinical pharmacology

Walzer N, Flamm SL.
PMID: 24422772
Expert Rev Clin Pharmacol. 2009 Jan;2(1):67-76. doi: 10.1586/17512433.2.1.67.

Hepatitis C virus (HCV) is one of the most common causes of chronic liver disease and is currently the leading indication for liver transplantation in the USA. Pegylated IFN-α (PEG-IFN-α) and ribavirin comprise the standard of care for the...

Cite
Walzer N, Flamm SL. Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations. Expert Rev Clin Pharmacol. 2009;2(1):67-76doi: 10.1586/17512433.2.1.67.
Walzer, N., & Flamm, S. L. (2009). Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations. Expert review of clinical pharmacology, 2(1), 67-76. https://doi.org/10.1586/17512433.2.1.67
Walzer, Natasha, and Flamm, Steven L. "Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations." Expert review of clinical pharmacology vol. 2,1 (2009): 67-76. doi: https://doi.org/10.1586/17512433.2.1.67
Walzer N, Flamm SL. Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations. Expert Rev Clin Pharmacol. 2009 Jan;2(1):67-76. doi: 10.1586/17512433.2.1.67. PMID: 24422772.
Copy Download .nbib Format: NLM
Words of wisdom. Re: Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Sylvester RJ, Brausi MA, Kirkels WJ, et al.

European urology

Lamm DL.
PMID: 21531192
Eur Urol. 2011 Jun;59(6):1065. doi: 10.1016/j.eururo.2011.03.040.

No abstract available.

Cite
Lamm DL. Words of wisdom. Re: Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Sylvester RJ, Brausi MA, Kirkels WJ, et al. Eur Urol. 2011;59(6):1065doi: 10.1016/j.eururo.2011.03.040.
Lamm, D. L. (2011). Words of wisdom. Re: Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Sylvester RJ, Brausi MA, Kirkels WJ, et al. European urology, 59(6), 1065. https://doi.org/10.1016/j.eururo.2011.03.040
Lamm, Donald L. "Words of wisdom. Re: Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Sylvester RJ, Brausi MA, Kirkels WJ, et al." European urology vol. 59,6 (2011): 1065. doi: https://doi.org/10.1016/j.eururo.2011.03.040
Lamm DL. Words of wisdom. Re: Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Sylvester RJ, Brausi MA, Kirkels WJ, et al. Eur Urol. 2011 Jun;59(6):1065. doi: 10.1016/j.eururo.2011.03.040. PMID: 21531192.
Copy Download .nbib Format: NLM
Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.

Urologic oncology

Lamm DL, Blumenstein BA, David Crawford E, Crissman JD, Lowe BA, Smith JA, Sarosdy MF, Schellhammer PF, Sagalowsky AI, Messing EM, Loehrer P, Barton Grossman H.
PMID: 21224104
Urol Oncol. 1995 May-Jun;1(3):119-26. doi: 10.1016/1078-1439(95)00041-f.

To compare the toxicity and efficacy of intravesical bacillus Calmette-Guérin (BCG) immunotherapy and mitomycin C (MMC) chemotherapy in the prophylaxis of recurrent transitional cell carcinoma, 469 patients with completely resected stage Ta or TI transitional cell carcinoma were enrolled...

Cite
Lamm DL, Blumenstein BA, David Crawford E, et al. Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol. 1995;1(3):119-26doi: 10.1016/1078-1439(95)00041-f.
Lamm, D. L., Blumenstein, B. A., David Crawford, E., Crissman, J. D., Lowe, B. A., Smith, J. A., Sarosdy, M. F., Schellhammer, P. F., Sagalowsky, A. I., Messing, E. M., Loehrer, P., & Barton Grossman, H. (1995). Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urologic oncology, 1(3), 119-26. https://doi.org/10.1016/1078-1439(95)00041-f
Lamm, D L, et al. "Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study." Urologic oncology vol. 1,3 (1995): 119-26. doi: https://doi.org/10.1016/1078-1439(95)00041-f
Lamm DL, Blumenstein BA, David Crawford E, Crissman JD, Lowe BA, Smith JA, Sarosdy MF, Schellhammer PF, Sagalowsky AI, Messing EM, Loehrer P, Barton Grossman H. Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol. 1995 May-Jun;1(3):119-26. doi: 10.1016/1078-1439(95)00041-f. PMID: 21224104.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 163 entries